Mabvax Therapeutics Holdings Inc. (TELK) 5.5000 $TELK
MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Therapeutics Announces Stock Ticker Symbol Change to MBVX
PR Newswire - Fri Oct 10, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. ("MabVax"
, a clinical stage oncology drug development company, announced today that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "MBVX" (OTCQB: MBVX.) The previous trading symbol was "TELK" (OTCQB: TELK).
MabVax Therapeutics Enters Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Development of Anti-Cancer Therapeutics
PR Newswire - Wed Sep 10, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, announced today it has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics (Juno) for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the Company's internally developed antibody discovery platform.
MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse Stock Split Resulting From Merger With Telik
PR Newswire - Tue Sep 09, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders have approved a change in the Company's name from Telik, Inc. to MabVax Therapeutics Holdings Inc., as well as a change in ticker symbol to MBVX that will likely take effect within the next three weeks. Stockholders also approved a reverse stock split at a ratio in the range of 1:5 to 1:15 and the authorization of additional common and preferred shares. These actions mark the completion of the actions that were originally intended to take effect at the time of the July 8, 2014 merger between MabVax and Telik. More than 70% of all outstanding shares voted in favor of all proposals in the proxy which was sent out on or about July 30, 2014.
Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers
PR Newswire - Thu Aug 28, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These preclinical test results demonstrate the potential for multiple antibody based therapeutic and diagnostic products based on this lead antibody development candidate.
Telik wins NCI's USD1.5m contract to develop novel antibody-based PET imaging agent for pancreatic cancer
M2 - Tue Aug 26, 6:49AM CDT
Oncology drug company Telik (Other OTC:TELK) disclosed on Monday that it has received a USD1.5m contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI).
Telik Receives $1.5 Million National Cancer Institute Contract to Develop Novel Antibody-based PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Aug 25, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center (MSKCC) to develop a novel Positron Emission Tomography (PET) imaging agent for detection and assessment of pancreatic cancer.
Telik Announces New Board of Director Members to Oversee Reinvigorated Cancer Therapy Pipeline Resulting from the Recent Merger with MabVax Therapeutics, Inc.
PR Newswire - Mon Aug 11, 8:00AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, which recently merged with MabVax Therapeutics, Inc. on July 8, 2014, announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger.
Telik Announces Plans for Special Meeting of Stockholders and Transition to MabVax Therapeutics Holdings, Inc.
PR Newswire - Mon Aug 04, 8:00AM CDT
As previously announced, MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (OTCQB: TELK), aclinical stage oncology drug development company, completed a merger transaction pursuant to which MabVax became a wholly owned subsidiary of Telik effective as of July 8, 2014, following Telik stockholder approval at Telik's annual meeting of stockholders, held on July 7, 2014. Following the merger, MabVax appointed and introduced a new management team and board of directors of Telik, which became effective on July 8, 2014. Management also filed a definitive proxy statement and set August 20, 2014, as a date for a special meeting of Stockholders to obtain approval for three proposals that failed to obtain the required number of votes for approval at Telik's annual meeting of stockholders. These three proposals require the approval of a majority of the shares of common stock and preferred stock of Telik, on an as-converted basis, at the special meeting, and, if such approval is obtained, would change Telik's name to MabVax Therapeutics Holdings, Inc., effect a 5 to 1 reverse stock split to meet NASDAQ initial listing requirements, and result in an increase in the number of authorized shares of common stock and preferred stock.
Mintz Levin Represents San Diego-Based MabVax Therapeutics, Inc. In IPO Through Merger with Telik, Inc.
Business Wire - Fri Jul 11, 9:13AM CDT
Attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s San Diego office represented San Diego-based MabVax Therapeutics, Inc. in its previously announced merger with a wholly owned subsidiary of Telik, Inc. (NASDAQ:TELK)
MabVax Therapeutics Raises $3 Million In Common Stock Financing And An Additional $1.5 Million Upon Exercise Of Series C-1 Warrants
PR Newswire - Wed Jul 09, 8:30AM CDT
MabVax Therapeutics, Inc., a privately held cancer immunotherapy company has closed a $3 Million common stock financing. MabVax entered into a securities purchase agreement with accredited investors for the sale of $3.0 million in a private placement of common stock of MabVax, which was completed prior to the closing of the merger with Telik, Inc. Investors paid $2.59 per share of MabVax common stock and will receive approximately 2.23 shares of Telik common stock for each share of MabVax common stock following consummation of the merger. H.C. Wainwright & Co., LLC, Palladium Capital Advisors LLC and Dawson James Securities assisted as placement agents in the transaction.
MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Therapeutics Announces Stock Ticker Symbol Change to MBVX
PR Newswire - Fri Oct 10, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. ("MabVax"
, a clinical stage oncology drug development company, announced today that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "MBVX" (OTCQB: MBVX.) The previous trading symbol was "TELK" (OTCQB: TELK). MabVax Therapeutics Enters Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Development of Anti-Cancer Therapeutics
PR Newswire - Wed Sep 10, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, announced today it has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics (Juno) for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the Company's internally developed antibody discovery platform.
MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse Stock Split Resulting From Merger With Telik
PR Newswire - Tue Sep 09, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders have approved a change in the Company's name from Telik, Inc. to MabVax Therapeutics Holdings Inc., as well as a change in ticker symbol to MBVX that will likely take effect within the next three weeks. Stockholders also approved a reverse stock split at a ratio in the range of 1:5 to 1:15 and the authorization of additional common and preferred shares. These actions mark the completion of the actions that were originally intended to take effect at the time of the July 8, 2014 merger between MabVax and Telik. More than 70% of all outstanding shares voted in favor of all proposals in the proxy which was sent out on or about July 30, 2014.
Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers
PR Newswire - Thu Aug 28, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These preclinical test results demonstrate the potential for multiple antibody based therapeutic and diagnostic products based on this lead antibody development candidate.
Telik wins NCI's USD1.5m contract to develop novel antibody-based PET imaging agent for pancreatic cancer
M2 - Tue Aug 26, 6:49AM CDT
Oncology drug company Telik (Other OTC:TELK) disclosed on Monday that it has received a USD1.5m contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI).
Telik Receives $1.5 Million National Cancer Institute Contract to Develop Novel Antibody-based PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Aug 25, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center (MSKCC) to develop a novel Positron Emission Tomography (PET) imaging agent for detection and assessment of pancreatic cancer.
Telik Announces New Board of Director Members to Oversee Reinvigorated Cancer Therapy Pipeline Resulting from the Recent Merger with MabVax Therapeutics, Inc.
PR Newswire - Mon Aug 11, 8:00AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, which recently merged with MabVax Therapeutics, Inc. on July 8, 2014, announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger.
Telik Announces Plans for Special Meeting of Stockholders and Transition to MabVax Therapeutics Holdings, Inc.
PR Newswire - Mon Aug 04, 8:00AM CDT
As previously announced, MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (OTCQB: TELK), aclinical stage oncology drug development company, completed a merger transaction pursuant to which MabVax became a wholly owned subsidiary of Telik effective as of July 8, 2014, following Telik stockholder approval at Telik's annual meeting of stockholders, held on July 7, 2014. Following the merger, MabVax appointed and introduced a new management team and board of directors of Telik, which became effective on July 8, 2014. Management also filed a definitive proxy statement and set August 20, 2014, as a date for a special meeting of Stockholders to obtain approval for three proposals that failed to obtain the required number of votes for approval at Telik's annual meeting of stockholders. These three proposals require the approval of a majority of the shares of common stock and preferred stock of Telik, on an as-converted basis, at the special meeting, and, if such approval is obtained, would change Telik's name to MabVax Therapeutics Holdings, Inc., effect a 5 to 1 reverse stock split to meet NASDAQ initial listing requirements, and result in an increase in the number of authorized shares of common stock and preferred stock.
Mintz Levin Represents San Diego-Based MabVax Therapeutics, Inc. In IPO Through Merger with Telik, Inc.
Business Wire - Fri Jul 11, 9:13AM CDT
Attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s San Diego office represented San Diego-based MabVax Therapeutics, Inc. in its previously announced merger with a wholly owned subsidiary of Telik, Inc. (NASDAQ:TELK)
MabVax Therapeutics Raises $3 Million In Common Stock Financing And An Additional $1.5 Million Upon Exercise Of Series C-1 Warrants
PR Newswire - Wed Jul 09, 8:30AM CDT
MabVax Therapeutics, Inc., a privately held cancer immunotherapy company has closed a $3 Million common stock financing. MabVax entered into a securities purchase agreement with accredited investors for the sale of $3.0 million in a private placement of common stock of MabVax, which was completed prior to the closing of the merger with Telik, Inc. Investors paid $2.59 per share of MabVax common stock and will receive approximately 2.23 shares of Telik common stock for each share of MabVax common stock following consummation of the merger. H.C. Wainwright & Co., LLC, Palladium Capital Advisors LLC and Dawson James Securities assisted as placement agents in the transaction.
